A new clinical trial investigating psilocybin as a treatment for severe, long-term depression has produced mixed results, finding that the psychedelic compound reduced symptoms meaningfully in some patients but failed to meet its primary goal. The findings add important nuance to the growing body of research into psilocybin therapy for treatment-resistant depression, a condition that affects millions of people who have not responded to conventional antidepressants.
The trial, known as EPISODE and published in JAMA Psychiatry, enrolled 144 adults in Germany who had failed to improve after at least two courses of antidepressant medication. Participants received either a high dose of synthetic psilocybin (25mg), a low dose (5mg), or an active placebo called nicotinamide, each administered alongside structured psychotherapy sessions. The study was triple-blinded, meaning that patients, therapists, and assessors were all kept unaware of which treatment had been given.
At the six-week primary endpoint, response rates were 17% for the high-dose group, 12.5% for the low-dose group, and 10.6% for those who received the placebo. This difference was not statistically significant, meaning the trial technically failed to prove psilocybin was superior. However, secondary measures told a more encouraging story, with high-dose psilocybin producing clinically meaningful reductions in depression scores compared with both the placebo and the low dose.
One week after the first dose, response rates in the high-dose group were notably higher at 34%, compared with just 6.4% for the placebo group. This early signal suggests that psilocybin’s antidepressant effects may emerge rapidly but fade over subsequent weeks, a pattern researchers say warrants further investigation. The question of whether this represents a genuine lasting change or a short-term “afterglow” effect remains unresolved.
By week 12, after all participants had received at least one high dose of psilocybin, symptom reductions were substantial across the board, with average scores on the Hamilton Depression Rating Scale falling by around 7.5 points. The researchers noted this reflects a meaningful improvement, though the study was not designed to draw firm conclusions at that stage.
Safety was also a concern. Adverse events were common in the high-dose group, particularly on dosing days, and included perceptual disturbances, paranoia, and heightened emotional sensitivity. Suicidal ideation on dosing days was reported in 4% of the high-dose group, compared with 1 to 2% in the other conditions. One participant developed hallucinogen persisting perception disorder, a rare condition in which visual disturbances continue long after drug use.
The researchers acknowledge that the trial was likely underpowered, as the expected treatment effect had been overestimated based on earlier, smaller studies. They call for larger, better-resourced confirmatory trials with longer follow-up periods and more diverse patient samples.
Psilocybin therapy for treatment-resistant depression remains a significant area of psychiatric research, and despite the inconclusive primary outcome, its clinical potential has not been ruled out.